Pathology in United States: Leukemias – Pipeline Review, H1 2012

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 436 pages

This report provides information on the therapeutic development for Leukemias, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Leukemias. 'Leukemias - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope of the Research

- A snapshot of the global therapeutic scenario for Leukemias.
- A review of the Leukemias products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Leukemias pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Identify and understand important and diverse types of therapeutics under development for Leukemias.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Leukemias pipeline depth and focus of Leukemias therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 17
Introduction 18
Global March kets Direct Report Coverage 18
Leukemias Overview 19
Therapeutics Development 20
An Overview of Pipeline Products for Leukemias 20
Leukemias Therapeutics under Development by Firms 22
Leukemias Therapeutics under Investigation by Universities/Institutes 35
Late Stage Products 54
Comparative Analysis 54
Mid Clinical Stage Products 55
Comparative Analysis 55
Early Clinical Stage Products 56
Comparative Analysis 56
Discovery and Pre-Clinical Stage Products 57
Comparative Analysis 57
Leukemias Therapeutics - Products under Development by Firms 58
Leukemias Therapeutics - Products under Investigation by Universities/Institutes 79
Companies Involved in Leukemias Therapeutics Development 173
Bristol-Myers Squibb Firms 173
Genzyme Corporation 174
Johnson and Johnson 175
Boehringer Ingelheim GmbH 176
F. Hoffmann-La Roche Ltd. 177
Kyowa Hakko Kirin Co., Ltd. 178
Abbott Laboratories 179
Amgen Inc. 180
Sanofi-Aventis 181
AstraZeneca PLC 182
Eli Lilly and Firms 183
Athersys, Inc. 184
GlaxoSmithKline plc 185
Seattle Genetics, Inc. 186
Genentech, Inc. 187
Gilead Sciences, Inc. 188
Daiichi Sankyo Firms, Ltd 189
medac GmbH 190
Merck and Co., Inc. 191
Emergent BioSolutions Inc. 192
Lentigen Corporation 193
Micromet, Inc. 194
Gamida Cell Ltd. 195
Generex Biotechnology Corporation 196
Albany Molecular Research, Inc. 197
Celltrion, Inc. 198
Bio-Path Holdings, Inc. 199
BioSante Pharmaceuticals, Inc. 200
Aldagen, Inc. 201
ZIOPHARM Oncology, Inc. 202
Millennium Pharmaceuticals, Inc. 203
November artis AG 204
BioMarch in Pharmaceutical Inc. 205
Cephalon, Inc. 206
Eisai Co., Ltd. 207
Glenmark Pharmaceuticals Ltd. 208
Hanmi Pharmaceutical Co Ltd 209
ImmunoGen, Inc. 210
Nippon Shinyaku Co., Ltd. 211
Pfizer Inc. 212
Sunesis Pharmaceuticals, Inc. 213
SuperGen, Inc. 214
Genmab A/S 215
Enzon Pharmaceuticals, Inc. 216
Santaris Pharma A/S 217
Cyclacel Pharmaceuticals Inc. 218
Alfacell Corporation 219
Celgene Corporation 220
Bayer AG 221
Incyte Corporation 222
Geron Corporation 223
Merck KGaA 224
Access Pharmaceuticals, Inc. 225
4SC AG 226
EntreMed, Inc. 227
EpiCept Corporation 228
Hana Biosciences, Inc. 229
Celldex Therapeutics, Inc. 230
AEterna Zentaris Inc. 231
IMMUNOMEDICS, INC 232
InNexus Biotechnology Inc. 233
Ligand Pharmaceuticals Incorporated 234
Ariad Pharmaceuticals, Inc. 235
Lorus Therapeutics Inc 236
Avalon Pharmaceuticals, Inc. 237
MethylGene Inc 238
Northwest Biotherapeutics, Inc. 239
Cleveland BioLabs, Inc. 240
OncoVista Innovative Therapies, Inc. 241
OXiGENE, Inc. 242
Critical Outcome Technologies Inc. 243
Alexion Pharmaceuticals, Inc. 244
BioCryst Pharmaceuticals, Inc. 245
Portola Pharmaceuticals, Inc. 246
CSL Limited 247
Telik, Inc. 248
TopoTarget A/S 249
VioQuest Pharmaceuticals, Inc. 250
CytRx Corporation 251
Pharmacyclics, Inc. 252
Array BioPharma Inc. 253
MorphoSys AG 254
Choongwae Pharma Corp 255
Threshold Pharmaceuticals, Inc. 256
Synta Pharmaceuticals Corp. 257
CrystalGenomics, Inc. 258
BioAlliance Pharma SA 259
Natco Pharma Limited 260
Sareum Holdings plc 261
Clavis Pharma ASA 262
Innate Pharma SA 263
Simcere Pharmaceutical Group 264
Piramal Life Sciences Limited 265
SymBio Pharmaceuticals Limited 266
Cellerant Therapeutics, Inc. 267
InDex Pharmaceuticals AB 268
Debiopharm Group 269
Chroma Therapeutics Ltd. 270
Avaris 271
Ambit Biosciences Corporation 272
Immupharma Plc 273
Memgen, LLC. 274
Actinium Pharmaceuticals, Inc. 275
Abiogen Pharma S.p.A. 276
BioMAS Ltd. 277
ERYtech Pharma 278
ViroStatics, srl 279
Curacyte AG 280
Aquinox Pharmaceuticals Inc. 281
Celator Pharmaceuticals, Inc. 282
Altor BioScience Corporation 283
Ascenta Therapeutics, Inc. 284
TMRC Co., Ltd. 285
Coronado Biosciences, Inc. 286
Arno Therapeutics, Inc. 287
ACT Biotech, Inc. 288
TetraLogic Pharmaceuticals 289
Celentyx Ltd. 290
Semafore Pharmaceuticals, Inc. 291
S*BIO Pte Ltd 292
December iphera Pharmaceuticals, LLC 293
Xigen SA 294
Affichem 295
Stemline Therapeutics, Inc. 296
Avila Therapeutics, Inc. 297
Proacta, Inc. 298
Cornerstone Pharmaceuticals, Inc. 299
Polyphenon Pharma 300
Advenchen Laboratories, LLC 301
Onconova Therapeutics, Inc 302
MolMed S.p.A. 303
Syndax Pharmaceuticals, Inc. 304
Myriad Pharmaceuticals, Inc. 305
NOXXON Pharma AG 306
Juvaris BioTherapeutics, Inc. 307
Esperance Pharmaceuticals, Inc. 308
Mirna Therapeutics, Inc. 309
Omeros Corporation 310
Trillium Therapeutics Inc. 311
Globeimmune, Inc. 312
SBI Biotech Co., Ltd. 313
PharmaMarch, S.A. 314
KaloBios Pharmaceuticals, Inc. 315
April ea AB. 316
Kinex Pharmaceuticals, LLC 317
OncoImmune, Inc. 318
Cylene Pharmaceuticals, Inc. 319
SymbioTec GmbH 320
GlycoMimetics, Inc. 321
Biothera 322
Nereus Pharmaceuticals, Inc. 323
Advanced Cancer Therapeutics 324
Cellceutix Pharmaceuticals, Inc. 325
Sigma-Tau Pharmaceuticals, Inc. 326
The Alize Pharma Group 327
LFB Biotechnologies, S.A.S.U. 328
Interprotein Corporation 329
EpiZyme, Inc. 330
Targa Therapeutics Corp. 331
Sentinel Oncology Limited 332
Polaris Group 333
ImQuest Life Sciences 334
The Vaccine Firms L.P. 335
Immunovative Therapies, Ltd. 336
BerGenBio AS 337
Advancell 338
Leukemias - Therapeutics Assessment 339
Assessment by Monotherapy Products 339
Assessment by Combination Products 340
Assessment by Route of Administration 341
Assessment by Molecule Type 344
Drug Profiles 347
StemEx - Drug Profile 347
Bosutinib - Drug Profile 349
RG7159 - Drug Profile 351
PKC412 - Drug Profile 352
AP24534 - Drug Profile 353
Vosaroxin - Drug Profile 355
Dacogen - Drug Profile 357
AMG-761 - Drug Profile 359
Graspa - Drug Profile 361
Ceplene - Drug Profile 363
March qibo - Drug Profile 365
Omapro - Drug Profile 367
Omapro - Drug Profile 369
Sapacitabine - Drug Profile 371
ELACYT - Drug Profile 373
Campath + Fludara - Drug Profile 375
TK Cells - Drug Profile 376
Vosaroxin + Cytarabine - Drug Profile 378
Aldesleukin + Ceplene - Drug Profile 380
Treosulfan - Drug Profile 381
PR1 Leukemia Peptide Vaccine + Sargramostim - Drug Profile 382
Revlimid - Drug Profile 383
Flucam - Drug Profile 385
Clolar + Cytarabine - Drug Profile 387
Cytarabine - Drug Profile 389
Arzerra + Fludarabine + Cyclophosphamide - Drug Profile 390
Ofatumumab + Chlorambucil - Drug Profile 392
RG7159 + Chlorambucil - Drug Profile 394
AZD1152 + Cytarabine - Drug Profile 395
Sapacitabine + December itabine - Drug Profile 397
EZN-2285 - Drug Profile 398
Leukemias Therapeutics - Drug Profile Updates 399
Leukemias Therapeutics - Discontinued Products 419
Leukemias Therapeutics - Dormant Products 433
Leukemias - Product Development Milestones 492
Featured News and Press Releases 492
Appendix 501
Methodology 501
Expert Panel Validation 502
Contact Us 502
Disclaimer 502

List of Tables

Number of Products Under Development for Leukemias, H1 2012 22
Products under Development for Leukemias - Comparative Analysis, H1 2012 23
Number of Products under Development by Firms, H1 2012 25
Number of Products under Development by Firms, H1 2012 (Contd..1) 26
Number of Products under Development by Firms, H1 2012 (Contd..2) 27
Number of Products under Development by Firms, H1 2012 (Contd..3) 28
Number of Products under Development by Firms, H1 2012 (Contd..4) 29
Number of Products under Development by Firms, H1 2012 (Contd..5) 30
Number of Products under Development by Firms, H1 2012 (Contd..6) 31
Number of Products under Development by Firms, H1 2012 (Contd..7) 32
Number of Products under Development by Firms, H1 2012 (Contd..8) 33
Number of Products under Development by Firms, H1 2012 (Contd..9) 34
Number of Products under Development by Firms, H1 2012 (Contd..10) 35
Number of Products under Development by Firms, H1 2012 (Contd..11) 36
Number of Products under Investigation by Universities/Institutes, H1 2012 38
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 39
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 40
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 41
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 42
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 43
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 44
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 45
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 46
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 47
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 48
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 49
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..12) 50
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..13) 51
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..14) 52
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..15) 53
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..16) 54
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..17) 55
Comparative Analysis by Late Stage Development, H1 2012 56
Comparative Analysis by Mid Clinical Stage Development, H1 2012 57
Comparative Analysis by Early Clinical Stage Development, H1 2012 58
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 59
Products under Development by Firms, H1 2012 60
Products under Development by Firms, H1 2012 (Contd..1) 61
Products under Development by Firms, H1 2012 (Contd..2) 62
Products under Development by Firms, H1 2012 (Contd..3) 63
Products under Development by Firms, H1 2012 (Contd..4) 64
Products under Development by Firms, H1 2012 (Contd..5) 65
Products under Development by Firms, H1 2012 (Contd..6) 66
Products under Development by Firms, H1 2012 (Contd..7) 67
Products under Development by Firms, H1 2012 (Contd..8) 68
Products under Development by Firms, H1 2012 (Contd..9) 69
Products under Development by Firms, H1 2012 (Contd..10) 70
Products under Development by Firms, H1 2012 (Contd..11) 71
Products under Development by Firms, H1 2012 (Contd..12) 72
Products under Development by Firms, H1 2012 (Contd..13) 73
Products under Development by Firms, H1 2012 (Contd..14) 74
Products under Development by Firms, H1 2012 (Contd..15) 75
Products under Development by Firms, H1 2012 (Contd..16) 76
Products under Development by Firms, H1 2012 (Contd..17) 77
Products under Development by Firms, H1 2012 (Contd..18) 78
Products under Development by Firms, H1 2012 (Contd..19) 79
Products under Development by Firms, H1 2012 (Contd..20) 80
Products under Investigation by Universities/Institutes, H1 2012 81
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 82
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 83
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 84
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 85
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 86
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 87
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 88
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 89
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 90
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 92
Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 93
Products under Investigation by Universities/Institutes, H1 2012 (Contd..12) 95
Products under Investigation by Universities/Institutes, H1 2012 (Contd..13) 96
Products under Investigation by Universities/Institutes, H1 2012 (Contd..14) 97
Products under Investigation by Universities/Institutes, H1 2012 (Contd..15) 98
Products under Investigation by Universities/Institutes, H1 2012 (Contd..16) 99
Products under Investigation by Universities/Institutes, H1 2012 (Contd..17) 100
Products under Investigation by Universities/Institutes, H1 2012 (Contd..18) 101
Products under Investigation by Universities/Institutes, H1 2012 (Contd..19) 102
Products under Investigation by Universities/Institutes, H1 2012 (Contd..20) 103
Products under Investigation by Universities/Institutes, H1 2012 (Contd..21) 104
Products under Investigation by Universities/Institutes, H1 2012 (Contd..22) 105
Products under Investigation by Universities/Institutes, H1 2012 (Contd..23) 106
Products under Investigation by Universities/Institutes, H1 2012 (Contd..24) 107
Products under Investigation by Universities/Institutes, H1 2012 (Contd..25) 108
Products under Investigation by Universities/Institutes, H1 2012 (Contd..26) 109
Products under Investigation by Universities/Institutes, H1 2012 (Contd..27) 110
Products under Investigation by Universities/Institutes, H1 2012 (Contd..28) 111
Products under Investigation by Universities/Institutes, H1 2012 (Contd..29) 112
Products under Investigation by Universities/Institutes, H1 2012 (Contd..30) 113
Products under Investigation by Universities/Institutes, H1 2012 (Contd..31) 114
Products under Investigation by Universities/Institutes, H1 2012 (Contd..32) 115
Products under Investigation by Universities/Institutes, H1 2012 (Contd..33) 116
Products under Investigation by Universities/Institutes, H1 2012 (Contd..34) 117
Products under Investigation by Universities/Institutes, H1 2012 (Contd..35) 119
Products under Investigation by Universities/Institutes, H1 2012 (Contd..36) 120
Products under Investigation by Universities/Institutes, H1 2012 (Contd..37) 121
Products under Investigation by Universities/Institutes, H1 2012 (Contd..38) 122
Products under Investigation by Universities/Institutes, H1 2012 (Contd..39) 123
Products under Investigation by Universities/Institutes, H1 2012 (Contd..40) 124
Products under Investigation by Universities/Institutes, H1 2012 (Contd..41) 125
Products under Investigation by Universities/Institutes, H1 2012 (Contd..42) 126
Products under Investigation by Universities/Institutes, H1 2012 (Contd..43) 127
Products under Investigation by Universities/Institutes, H1 2012 (Contd..44) 128
Products under Investigation by Universities/Institutes, H1 2012 (Contd..45) 129
Products under Investigation by Universities/Institutes, H1 2012 (Contd..46) 130
Products under Investigation by Universities/Institutes, H1 2012 (Contd..47) 131
Products under Investigation by Universities/Institutes, H1 2012 (Contd..48) 132
Products under Investigation by Universities/Institutes, H1 2012 (Contd..49) 133
Products under Investigation by Universities/Institutes, H1 2012 (Contd..50) 134
Products under Investigation by Universities/Institutes, H1 2012 (Contd..51) 135
Products under Investigation by Universities/Institutes, H1 2012 (Contd..52) 136
Products under Investigation by Universities/Institutes, H1 2012 (Contd..53) 137
Products under Investigation by Universities/Institutes, H1 2012 (Contd..54) 138
Products under Investigation by Universities/Institutes, H1 2012 (Contd..55) 139
Products under Investigation by Universities/Institutes, H1 2012 (Contd..56) 140
Products under Investigation by Universities/Institutes, H1 2012 (Contd..57) 141
Products under Investigation by Universities/Institutes, H1 2012 (Contd..58) 142
Products under Investigation by Universities/Institutes, H1 2012 (Contd..59) 143
Products under Investigation by Universities/Institutes, H1 2012 (Contd..60) 144
Products under Investigation by Universities/Institutes, H1 2012 (Contd..61) 145
Products under Investigation by Universities/Institutes, H1 2012 (Contd..62) 146
Products under Investigation by Universities/Institutes, H1 2012 (Contd..63) 147
Products under Investigation by Universities/Institutes, H1 2012 (Contd..64) 148
Products under Investigation by Universities/Institutes, H1 2012 (Contd..65) 149
Products under Investigation by Universities/Institutes, H1 2012 (Contd..66) 150
Products under Investigation by Universities/Institutes, H1 2012 (Contd..67) 151
Products under Investigation by Universities/Institutes, H1 2012 (Contd..68) 152
Products under Investigation by Universities/Institutes, H1 2012 (Contd..69) 153
Products under Investigation by Universities/Institutes, H1 2012 (Contd..70) 154
Products under Investigation by Universities/Institutes, H1 2012 (Contd..71) 155
Products under Investigation by Universities/Institutes, H1 2012 (Contd..72) 156
Products under Investigation by Universities/Institutes, H1 2012 (Contd..73) 157
Products under Investigation by Universities/Institutes, H1 2012 (Contd..74) 158
Products under Investigation by Universities/Institutes, H1 2012 (Contd..75) 159
Products under Investigation by Universities/Institutes, H1 2012 (Contd..76) 160
Products under Investigation by Universities/Institutes, H1 2012 (Contd..77) 161
Products under Investigation by Universities/Institutes, H1 2012 (Contd..78) 162
Products under Investigation by Universities/Institutes, H1 2012 (Contd..79) 163
Products under Investigation by Universities/Institutes, H1 2012 (Contd..80) 164
Products under Investigation by Universities/Institutes, H1 2012 (Contd..81) 165
Products under Investigation by Universities/Institutes, H1 2012 (Contd..82) 166
Products under Investigation by Universities/Institutes, H1 2012 (Contd..83) 167
Products under Investigation by Universities/Institutes, H1 2012 (Contd..84) 168
Products under Investigation by Universities/Institutes, H1 2012 (Contd..85) 169
Products under Investigation by Universities/Institutes, H1 2012 (Contd..86) 170
Products under Investigation by Universities/Institutes, H1 2012 (Contd..87) 171
Products under Investigation by Universities/Institutes, H1 2012 (Contd..88) 172
Products under Investigation by Universities/Institutes, H1 2012 (Contd..89) 173
Products under Investigation by Universities/Institutes, H1 2012 (Contd..90) 174
Bristol-Myers Squibb Firms, H1 2012 175
Genzyme Corporation, H1 2012 176
Johnson and Johnson, H1 2012 177
Boehringer Ingelheim GmbH, H1 2012 178
F. Hoffmann-La Roche Ltd., H1 2012 179
Kyowa Hakko Kirin Co., Ltd., H1 2012 180
Abbott Laboratories, H1 2012 181
Amgen Inc., H1 2012 182
Sanofi-Aventis, H1 2012 183
AstraZeneca PLC, H1 2012 184
Eli Lilly and Firms, H1 2012 185
Athersys, Inc., H1 2012 186
GlaxoSmithKline plc, H1 2012 187
Seattle Genetics, Inc., H1 2012 188
Genentech, Inc., H1 2012 189
Gilead Sciences, Inc., H1 2012 190
Daiichi Sankyo Firms, Ltd, H1 2012 191
medac GmbH, H1 2012 192
Merck and Co., Inc., H1 2012 193
Emergent BioSolutions Inc., H1 2012 194
Lentigen Corporation, H1 2012 195
Micromet, Inc., H1 2012 196
Gamida Cell Ltd., H1 2012 197
Generex Biotechnology Corporation, H1 2012 198
Albany Molecular Research, Inc., H1 2012 199
Celltrion, Inc., H1 2012 200
Bio-Path Holdings, Inc., H1 2012 201
BioSante Pharmaceuticals, Inc., H1 2012 202
Aldagen, Inc., H1 2012 203
ZIOPHARM Oncology, Inc., H1 2012 204
Millennium Pharmaceuticals, Inc., H1 2012 205
November artis AG, H1 2012 206
BioMarch in Pharmaceutical Inc., H1 2012 207
Cephalon, Inc., H1 2012 208
Eisai Co., Ltd., H1 2012 209
Glenmark Pharmaceuticals Ltd., H1 2012 210
Hanmi Pharmaceutical Co Ltd, H1 2012 211
ImmunoGen, Inc., H1 2012 212
Nippon Shinyaku Co., Ltd., H1 2012 213
Pfizer Inc., H1 2012 214
Sunesis Pharmaceuticals, Inc., H1 2012 215
SuperGen, Inc., H1 2012 216
Genmab A/S, H1 2012 217
Enzon Pharmaceuticals, Inc., H1 2012 218
Santaris Pharma A/S, H1 2012 219
Cyclacel Pharmaceuticals Inc., H1 2012 220
Alfacell Corporation, H1 2012 221
Celgene Corporation, H1 2012 222
Bayer AG, H1 2012 223
Incyte Corporation, H1 2012 224
Geron Corporation, H1 2012 225
Merck KGaA, H1 2012 226
Access Pharmaceuticals, Inc., H1 2012 227
4SC AG, H1 2012 228
EntreMed, Inc., H1 2012 229
EpiCept Corporation, H1 2012 230
Hana Biosciences, Inc., H1 2012 231
Celldex Therapeutics, Inc., H1 2012 232
AEterna Zentaris Inc., H1 2012 233
IMMUNOMEDICS, INC, H1 2012 234
InNexus Biotechnology Inc., H1 2012 235
Ligand Pharmaceuticals Incorporated, H1 2012 236
Ariad Pharmaceuticals, Inc., H1 2012 237
Lorus Therapeutics Inc, H1 2012 238
Avalon Pharmaceuticals, Inc., H1 2012 239
MethylGene Inc, H1 2012 240
Northwest Biotherapeutics, Inc., H1 2012 241
Cleveland BioLabs, Inc., H1 2012 242
OncoVista Innovative Therapies, Inc., H1 2012 243
OXiGENE, Inc., H1 2012 244

List of Figures

Number of Products under Development for Leukemias, H1 2012 22
Products under Development for Leukemias - Comparative Analysis, H1 2012 23
Products under Development by Firms, H1 2012 24
Products under Investigation by Universities/Institutes, H1 2012 37
Late Stage Products, H1 2012 56
Mid Clinical Stage Products, H1 2012 57
Early Clinical Stage Products, H1 2012 58
Discovery and Pre-Clinical Stage Products, H1 2012 59
Assessment by Monotherapy Products, H1 2012 341
Assessment by Combination Products, H1 2012 342
Assessment by Route of Administration, H1 2012 343
Assessment by Stage and Route of Administration, H1 2012 344
Assessment by Molecule Type, H1 2012 346
Assessment by Stage and Molecule Type, H1 2012 347

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

World Therapy: Postherpetic Neuralgia – Pipeline Review, H1 2012

World Therapy: Postherpetic Neuralgia – Pipeline Review, H1 2012

  • $ 2 000
  • Company report
  • March 2014
  • by Global Markets Direct

This report provides data on the therapeutic development for Postherpetic Neuralgia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players ...

World Therapy: Wounds – Pipeline Review, H1 2012

World Therapy: Wounds – Pipeline Review, H1 2012

  • $ 2 000
  • Company report
  • April 2014
  • by Global Markets Direct

This report provides data on the therapeutic development for Wounds, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in ...

World Pathology: Diabetic Nephropathy – Pipeline Review, H1 2012

World Pathology: Diabetic Nephropathy – Pipeline Review, H1 2012

  • $ 2 000
  • Company report
  • March 2014
  • by Global Markets Direct

This report provides data on the therapeutic development for Diabetic Nephropathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.